Pulse Brain · Growing Health Evidence Index
Peer-reviewed

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk

Fredrik Landfors, Peter Henneman, Elin Chorell, Stefan K. Nilsson, Sander Kersten

European Heart Journal Open · 2024

Read source ↗ All evidence

Summary

Human genetic evidence suggests that therapies aimed at reducing circulating levels of ANGPTL3, ANGPTL4, and APOC3 reduce the risk of CAD. ANGPTL4 lowering may also reduce the risk of T2D.

Source type
Peer-reviewed study
DOI
10.1093/ehjopen/oeae035
Catalogue ID
SNmohbb2ol-8bki02
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.

How does this finding apply in a UK context?→What are the most cited records on this topic?→